{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:43:55Z","timestamp":1769085835787,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014916","name":"DAK-Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024074","name":"Techniker Krankenkasse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2024.10.007","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T11:02:55Z","timestamp":1729335775000},"page":"563-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence, incidence, and treatment of dyslipidemia in patients with high or very high cardiovascular risk in Germany"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-323X","authenticated-orcid":false,"given":"Julian","family":"Witte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Batram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-5243","authenticated-orcid":false,"given":"Magnus","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika-Anina","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Weing\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacl.2024.10.007_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2024.10.007_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European atherosclerosis society task force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2024.10.007_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2024.10.007_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40292-016-0155-2","article-title":"Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk","volume":"23","author":"Agabiti Rosei","year":"2016","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"09","key":"10.1016\/j.jacl.2024.10.007_bib0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/a-1190-8023","article-title":"Von der Di\u00e4t bis zu Lipoproteinapherese","volume":"24","author":"Schettler","year":"2020","journal-title":"Dialyse aktuell"},{"issue":"3","key":"10.1016\/j.jacl.2024.10.007_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2459\/JCM.0000000000001108","article-title":"Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper","volume":"22","author":"Colivicchi","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"15","key":"10.1016\/j.jacl.2024.10.007_bib0007","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1055\/a-1516-2631","article-title":"Therapieoptionen zur LDL-C-Senkung zus\u00e4tzlich zu Statinen","volume":"147","author":"Weing\u00e4rtner","year":"2022","journal-title":"Dtsch Med Wochenschr"},{"issue":"6","key":"10.1016\/j.jacl.2024.10.007_bib0008","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1055\/s-0042-123977","article-title":"Sekund\u00e4rdatenanalyse zur Ermittlung der Pr\u00e4valenz von kardiovaskul\u00e4ren Hochrisiko-Patienten mit Hypercholesterin\u00e4mie und therapierefrakt\u00e4rem Behandlungsverlauf","volume":"142","author":"Dippel","year":"2017","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"10.1016\/j.jacl.2024.10.007_bib0009","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","article-title":"Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins","volume":"107","author":"Fox","year":"2018","journal-title":"Clin Res Cardiol"},{"issue":"14","key":"10.1016\/j.jacl.2024.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"S 01","key":"10.1016\/j.jacl.2024.10.007_bib0011","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1055\/s-0042-108647","article-title":"A consensus german reporting standard for secondary data analyses, version 2 (STROSA-STandardisierte BerichtsROutine f\u00fcr Sekund\u00e4rdatenAnalysen)","volume":"78","author":"Swart","year":"2016","journal-title":"Gesundheitswesen"},{"issue":"10097","key":"10.1016\/j.jacl.2024.10.007_bib0012","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","article-title":"Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition","volume":"390","author":"Busse","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.jacl.2024.10.007_bib0013","unstructured":"Bundesministerium f\u00fcr Gesundheit. Mitglieder und Versicherte der Gesetzlichen Krankenversicherung (GKV): statistik uber Versicherte, gegliedert nach Status, Alter, Wohnort und Kassenart; 2020."},{"key":"10.1016\/j.jacl.2024.10.007_bib0014","series-title":"Health Care Utilization in Germany: Theory, Methodology, and Results","first-page":"63","article-title":"Health care utilization research using secondary data","author":"Swart","year":"2014"},{"issue":"3","key":"10.1016\/j.jacl.2024.10.007_bib0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","article-title":"Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-C","volume":"111","author":"Katzmann","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacl.2024.10.007_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CEOR.S347085","article-title":"Prevalence and patient outcomes of adult primary hypercholesterolemia and dyslipidemia in the UK: longitudinal retrospective study using a primary care dataset from 2009 to 2019","volume":"14","author":"Bilitou","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jacl.2024.10.007_bib0017","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.atherosclerosis.2006.02.025","article-title":"Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany","volume":"190","author":"B\u00f6hler","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.10.007_bib0018","unstructured":"R.K.I. Prevalence, incidence and mortality of diabetes mellitus in adults in Germany \u2013 a review in the framework of the Diabetes Surveillance. RKI-Bib1 (Robert Koch-Institut); 2017."},{"key":"10.1016\/j.jacl.2024.10.007_bib0019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1475-2840-11-50","article-title":"Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies","volume":"11","author":"R\u00fcckert","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacl.2024.10.007_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12944-020-01277-9","article-title":"Hyperlipidemias in elderly patients: results from the Berlin aging study II (BASEII), a cross-sectional study","volume":"19","author":"Rosada","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"18","key":"10.1016\/j.jacl.2024.10.007_bib0021","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2024.10.007_bib0022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany","volume":"268","author":"M\u00e4rz","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.10.007_bib0023","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1016\/j.jval.2019.09.805","article-title":"PCV81 current trends in lipid lowering therapy use in Germany","volume":"22","author":"Laufs","year":"2019","journal-title":"Value Health"},{"issue":"25","key":"10.1016\/j.jacl.2024.10.007_bib0024","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.10.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2024.10.007_bib0026","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00108-021-01059-0","article-title":"Diagnostik und therapie von statinassoziierten muskelsymptomen","volume":"62","author":"Kassner","year":"2021","journal-title":"Internist (Berl)"},{"key":"10.1016\/j.jacl.2024.10.007_bib0027","series-title":"Garbage in Garbage Out? Morbidity Oriented Budgets For GPs and Validity of Coded Diagnoses from GP Claims Records","author":"Erler","year":"2007"},{"key":"10.1016\/j.jacl.2024.10.007_bib0028","unstructured":"Gute Praxis Sekund\u00e4rdatenanalyse (GPS)Leitlinien und Empfehlungen: arbeitsgruppe Erhebung und Nutzung von Sekund\u00e4rdaten (AGENS) der Deutschen Gesell-schaft f\u00fcr Sozialmedizin und Pr\u00e4vention (DGSMP) und der Deutschen Gesellschaft f\u00fcr Epi-demiologie (DGEpi): AGENS. AGENS; 2014."},{"key":"10.1016\/j.jacl.2024.10.007_bib0029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2021.11.021","article-title":"Prevention guidelines and ESC\/EAS guidelines for the treatment of dyslipidaemias: a look to the future","volume":"340","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:30:38Z","timestamp":1762561838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287424002654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287424002654"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.10.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence, incidence, and treatment of dyslipidemia in patients with high or very high cardiovascular risk in Germany","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}